|Day Low/High||568.01 / 579.00|
|52 Wk Low/High||305.63 / 577.25|
Who knew high finance was so easy? And why the heck was I working so hard? Fundamental analysis is so 1980s.
Investors continue to be more aggressive sellers of DXCM.
Right now, the market is furiously trying to price in a Blue Wave, and the health care sector is getting clobbered. But here's how I think things play out.
Both Apple and Tesla are chopping shares into pieces, which will let individual investors have a shot at buying them.
The charts of the maker of medical devices for monitoring diabetes suggest a pause in its shares may be ahead.
Negotiations on the next round of stimulus, more so than tension between Washington and Beijing, and more so than earnings season, will control short-term financial market performance.
The glucose monitoring company is in Jim Cramer's Covid-19 index.
There are simply an immense number of health and technology and safety companies coupled with businesses that thrive when you have to stay home.
Money movers are not buying protection for individual names, but they are starting to bet against the market en masse, while the Russell 2000 ran up 4% on Monday.
But don't throw up your arms yet -- here are names that could be golden opportunities.
The reason that the coronavirus hasn't mattered to the market is because the market keeps going up.
Newly confirmed cases of the Covid-19 virus spiked from Hubei Province in China, where the city of Wuhan is located. The number of related deaths increased as well.
Some of the best opportunities are in lesser-known niche markets such as medical devices and services.
Let's check the charts and indicators before answering the $64,000 question.
The maker of glucose monitoring equipment saw its shares shoot higher last week on a big earnings beat and the rise may not be over.
As for pressure on the Chinese side, I think a September 17.8% decline in exports to the U.S. compounded on top of a 22% decline in August speaks for itself.
OPEC forecasts declining demand for OPEC oil, not a decline in global demand. That distinction is key.
Let's check the charts and indicators on the glucose-monitoring company.
What would the people who help determine AAPL's stock price really want?
In this day and age, companies must be 'disruptors' or get left in the dust.
With more gains likely on the charts let's come up with a strategy to take advantage of this opportunity.
Jim Cramer explains why his Action Alerts Plus charitable portfolio is hanging on to Abbott Laboratories.
After a slump early last year, the smartwatch's sales have been rebounding. New features unveiled at Apple's WWDC conference could aid its momentum later this year.